Pay in 4 interest-free payments of $6.64 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Funding This study review does not receive any funding in any form
In the SURPASS-2 trial, patients with obesity and T2D who received tirzeapatide (5 mg weekly) achieved greater HbA1c and body weight reductions than those receiving semaglutide (1 mg weekly) during the 40 week study (64) despite comparable putative GLP-1R occupancy at these doses (47)
Ramos-Casals, M
Warm autoimmune hemolytic anemia (wAIHA) research presented by Johnson & Johnson highlights profound disease burden and unmet need for targeted treatment options [press release]
US$ 20.37
US$ 23.43
US$ 25.15
US$ 24.13
US$ 29.33
US$ 20.22
US$ 21.81
US$ 21.55
US$ 23.33
